Trials / Terminated
TerminatedNCT05705167
Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)
A Multicentre, Open Label, Randomised, Controlled, Basket, Pragmatic, Phase II, Clinical and Translational Study to Determine the Efficacy and Safety of Plitidepsin Versus Control in Immunocompromised Adult Patients With Symptomatic COVID-19 Requiring Hospital Care
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- PharmaMar · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate efficacy of plitidepsin in pre-specified groups of immunocompromised patients with symptomatic COVID-19 requiring hospital care versus control in terms of mortality.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Plitidepsin | IV infusion over 60-minutes |
Timeline
- Start date
- 2023-04-19
- Primary completion
- 2024-03-19
- Completion
- 2024-04-19
- First posted
- 2023-01-30
- Last updated
- 2024-12-02
- Results posted
- 2024-12-02
Locations
44 sites across 11 countries: Belgium, France, Georgia, Greece, Hungary, Israel, Italy, Poland, Portugal, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT05705167. Inclusion in this directory is not an endorsement.